Ironwood Pharmaceuticals (NASDAQ:IRWD) Trading Down 4.3% – What’s Next?

Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) traded down 4.3% during mid-day trading on Wednesday . The company traded as low as $3.55 and last traded at $3.56. 61,270 shares were traded during mid-day trading, a decline of 98% from the average session volume of 2,827,905 shares. The stock had previously closed at $3.72.

Analysts Set New Price Targets

Several equities analysts have recently commented on IRWD shares. StockNews.com cut shares of Ironwood Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Tuesday, November 12th. Leerink Partnrs upgraded Ironwood Pharmaceuticals to a “hold” rating in a research note on Monday, September 9th. Finally, Leerink Partners began coverage on Ironwood Pharmaceuticals in a research report on Monday, September 9th. They issued a “market perform” rating and a $5.00 target price on the stock. Three equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $10.40.

Ironwood Pharmaceuticals Price Performance

The company has a fifty day simple moving average of $4.05 and a two-hundred day simple moving average of $5.04. The company has a market capitalization of $566.51 million, a P/E ratio of -115.00 and a beta of 0.41.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last released its quarterly earnings results on Thursday, November 7th. The biotechnology company reported $0.02 EPS for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.07). Ironwood Pharmaceuticals had a negative net margin of 0.65% and a negative return on equity of 0.96%. The firm had revenue of $91.60 million during the quarter, compared to the consensus estimate of $91.22 million. During the same period in the prior year, the business earned $0.12 EPS. The company’s revenue for the quarter was down 19.4% compared to the same quarter last year. Equities analysts anticipate that Ironwood Pharmaceuticals, Inc. will post 0.08 earnings per share for the current year.

Insiders Place Their Bets

In related news, CFO Sravan Kumar Emany sold 11,001 shares of the business’s stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $4.08, for a total transaction of $44,884.08. Following the completion of the transaction, the chief financial officer now owns 309,572 shares of the company’s stock, valued at approximately $1,263,053.76. The trade was a 3.43 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 12.90% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. KBC Group NV increased its holdings in shares of Ironwood Pharmaceuticals by 59.3% during the 3rd quarter. KBC Group NV now owns 8,593 shares of the biotechnology company’s stock worth $35,000 after purchasing an additional 3,198 shares during the period. CWM LLC lifted its position in Ironwood Pharmaceuticals by 55.1% in the second quarter. CWM LLC now owns 6,600 shares of the biotechnology company’s stock worth $43,000 after purchasing an additional 2,345 shares during the period. Wolverine Trading LLC acquired a new stake in shares of Ironwood Pharmaceuticals during the 3rd quarter valued at about $51,000. Diversified Trust Co acquired a new stake in Ironwood Pharmaceuticals during the third quarter valued at approximately $52,000. Finally, Legacy Capital Group California Inc. bought a new stake in Ironwood Pharmaceuticals in the third quarter valued at $59,000.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.